医学
中性粒细胞减少症
耐受性
内科学
紫杉醇
养生
胃肠病学
临床终点
临床研究阶段
癌症
化疗
化疗方案
实体瘤疗效评价标准
毒性
肿瘤科
外科
不利影响
临床试验
作者
Hiroyuki Narahara,Kazumasa Fujitani,Hiroya Takiuchi,Naotoshi Sugimoto,Kentaro Inoue,Noriya Uedo,Hideaki Tsukuma,Toshirnasa Tsujinaka,Hiroshi Furukawa,Tetsuo Taguchi
出处
期刊:Oncology
[S. Karger AG]
日期:2008-01-01
卷期号:74 (1-2): 37-41
被引量:46
摘要
<i>Objectives:</i> A phase II study of weekly paclitaxel combined with S-1, a novel oral fluoropyrimidine, was performed to evaluate the efficacy and tolerability in unresectable or metastatic gastric cancer. <i>Patients and Methods:</i> Twenty-nine patients with unresectable and/or metastatic gastric cancer were enrolled in the study. Paclitaxel 50 mg/m<sup>2</sup> was administered on days 1 and 8. S-1 was administered orally at 40 mg/m<sup>2</sup> b.i.d. for 14 consecutive days, followed by a 1-week rest. The primary endpoint was the response rate. Secondary endpoints were safety and overall survival. <i>Results:</i> The overall response rate in 29 patients was 48.3%, differentiated 36.4% and undifferentiated 55.6%. The median survival time was 13.9 months. Grade 3 or higher toxicity was observed in neutropenia (3.4%), diarrhea (3.4%), bilirubin (3.4%) and neuropathy (3.4%). <i>Conclusions:</i> Combination chemotherapy of weekly paclitaxel and S-1 demonstrated tolerable toxicity and efficacy. This regimen will be one of the initial treatment options for unresectable or metastatic gastric cancer.
科研通智能强力驱动
Strongly Powered by AbleSci AI